肾康注射液对糖尿病肾病患者血清TGF-β1、sICAM-1水平的影响  

Effect of Shenkang Injection on Serum TGF-β1 and sICAM-1 Levels in Diabetic Nephropathy Patients

作　　者：郝峻岭[1] 孙学军[1] 童宁宁 HAO Jun-ling;SUN Xue-jun;TONG Ning-ning(Department of Nephrology,Weihai Municipal Hospital,Weihai Shandong 264200;Department of Nephrology,Weihai Hospital of Traditional Chinese Medicine,Weihai Shandong 264200)

机构地区：[1]山东省威海市立医院肾内科,山东威海264200 [2]山东省威海市中医院肾内科,山东威海264200

出　　处：《世界中西医结合杂志》2022年第7期1393-1396,1401,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：国家中医药管理局国家中医临床研究基地业务建设科研专项课题(JDZX2015307)。

摘　　要：目的探讨肾康注射液对糖尿病肾病(Diabetic nephropathy,DN)患者血清转化生长因子β1(Transforming factorβ1,TGF-β1)、可溶性细胞黏附分子1(Soluble cell adhesion molecule 1,sICAM-1)水平的影响。方法选取2017年6月—2020年6月期间山东省威海市立医院和山东省威海市中医收治的DN患者320例,采用随机信封法分为对照组和观察组,每组各160例。对照组采用缬沙坦治疗,在此基础上观察组加用肾康注射液治疗,两组患者治疗时间为4周。评价药物疗效及安全性,观察两组患者治疗前后症状[主症(气短懒言、咽干口燥、手足心热、倦怠乏力、腰膝酸软),次症(肢体麻木、面色无华、浮肿、心烦、易患感冒、便秘、夜尿频)]积分、生化指标[血肌酐(Serum creatinine,SCr)、尿β2-MG(urineβ2-MG,β2-MG)、24 h尿蛋白定量(24-hour urine protein quantification,24 h UP)]及血清TGF-β1、sICAM-1水平变化。结果治疗后观察组总有效率为91.88%(147/160)较对照组78.13%(125/160)明显升高,差异有统计学意义(P<0.05)。治疗后两组患者症状积分均较治疗前降低,差异有统计学意义(P<0.05);且观察组症状积分较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者血清SCr、尿β2-MG及24 h UP水平与治疗前比较均降低,差异有统计学意义(P<0.05);且观察组血清SCr、尿β2-MG及24 h UP水平较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者血清TGF-β1、sICAM-1水平与治疗前比较均降低,差异有统计学意义(P<0.05);且观察组血清TGF-β1、sICAM-1水平较对照组明显降低,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率5.00%(8/160)与对照组17.50%(28/160)比较明显减少,差异有统计学意义(P<0.05)。结论肾康注射液治疗DN的效果显著,能明显改善患者临床症状及肾功能,减轻DN患者炎症,抑制肾损伤,可能与降低血清TGF-β1、sICAM-1水平有关。Objective To investigate the effect of Shenkang Injection on serum transforming growth factor-β1(TGF-β1)and soluble cell adhesion molecule-1(sICAM-1)in patients with diabetic nephropathy(DN).Methods A total of 320 DN patients who were treated inWeihai Municipal Hospital and WeihaiHospital of Traditional Chinese Medicine from June 2017 to June 2020 were randomized into the control group and observation group,with 160 cases in either group.The control group was treated with valsartan,and the observation groupwith Shenkang Injection and valsartan.The treatment lasted 4 weeks for both groups.The efficacy and safety were evaluated and the syndrome[main symptoms(shortness of breath,distinclination to talk,dry throat and mouth,hot palms and soles,fatigueand lack of strength,soreness of waist and knees),minor symptoms(numbness of limbs,dim complexion,edema,dysphoria,ease of catching cold,constipation,and frequent nocturia)]score was recorded before and after treatment.Biochemical indexes[serum creatinine(SCR),urineβ2-MG,and 24 h urine protein(24 h UP)]and serum levels of TGF-β1 and sICAM-1 were measured.Results The total effective rate of the observation group was 91.88%(147/160),as compared with the 78.13%(125/160)in the control group(P<0.05).After treatment,the syndrome score was lower than before treatment for both groups(P<0.05)and lowerin the observation group(6.531.42)than in the control group(12.082.65)(P<0.05).After treatment,the levels of serum SCr,TGF-β1,sICAM-1,urineβ2-MG,and 24 hUP in the two groups were significantly lower than those before treatment(P<0.05),and the levels of the above biochemical indexes in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions was 17.50%(28/160)in the control group,as compared with the 5.00%(8/160)in the observation group(P<0.05).Conclusion Shenkang Injection can significantly alleviate clinical symptoms,inflammation,and renal injury in DN patients and improve therenal function,which may be related to the decrease

关 键 词：肾康注射液 糖尿病肾病 转化生长因子Β1 可溶性细胞黏附分子1 

分 类 号：R692[医药卫生—泌尿科学]